Richard Schilsky to Receptor, ErbB-2
This is a "connection" page, showing publications Richard Schilsky has written about Receptor, ErbB-2.
Connection Strength
0.658
-
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 06; 7:e2300041.
Score: 0.203
-
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 04; 7:e2200609.
Score: 0.201
-
Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. JCO Precis Oncol. 2022 10; 6:e2200306.
Score: 0.194
-
Cooperative group tissue banks as research resources: the cancer and leukemia group B tissue repositories. Clin Cancer Res. 2002 May; 8(5):943-8.
Score: 0.047
-
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002 Dec; 8(12):3718-27.
Score: 0.012